Why This Small-Cap Stock Is Gaining More Than 10% Today?

Chardan  has initiated coverage  of Immuneering Corp  (NASDAQ: IMRX ) with a Buy rating and a price target of $18. Immuneering's lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND filing, with potential for data 12-18 months later.  Chardan summarized the drivers as follows: IMM-1-104's CRAF bypass prevention mechanism and ~2-hour half-life differentiate it from approved and clinical-stage MEK inhibitors. Initial focus on ... Full story available on Benzinga.com